Begin main content

PCSK-9 Inhibitors for Hyperlipidemia: Comparative Clinical Effectiveness

Last updated: June 6, 2017
Project Number: RC0893-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary with Critical Appraisal
Result type: Report

Question

  1. What is the comparative clinical effectiveness of evolocumab versus alirocumab for the treatment of adults with heterozygous familial hyperlipidemia (HeFH) on maximally tolerated statin therapy who require additional lowering of low density lipoprotein cholesterol (LDL-C)?
  2. What is the comparative clinical effectiveness of evolocumab versus alirocumab for the treatment of adults with clinical atherosclerotic cardiovascular disease (CVD) on maximally tolerated statin therapy who require additional lowering of low density lipoprotein cholesterol (LDL-C)?

Key Message

A single non-randomized study reporting on comparative effects of alirocumab and evolocumab was identified. Considering the limitations of the study, no definitive conclusion on the comparative clinical effectiveness of alirocumab versus evolocumab in patients with heterozygous familial hyperlipidemia or cardiovascular disease was possible